What Proteologix does

Business model and revenue mechanics were characteristic of an early-stage biotech: the company was pre-revenue with no commercial products, no disclosed pricing, and no customer relationships. Value creation was driven by platform IP and pipeline progression rather than product sales. In June 2023, Proteologix received MilliporeSigma's 12th North American Advance Biotech Grant, providing in-kind R&D reagents, services, and expert consultation to advance its multi-specific molecule program. In June 2024, Johnson & Johnson acquired Proteologix for $850 million to bolster its dermatitis portfolio with assets targeting atopic dermatitis and asthma. Following the acquisition, Proteologix ceased to operate as an independent entity; its domain is now parked and its pipeline assets are managed within J&J's pharmaceutical segment. The deal formed part of a broader dermatology M&A wave totaling $6.4 billion across 33 transactions from 2024–2025.

Name

Proteologix

Legal name

Proteologix US Inc.

Website

https://proteologix.com

Company type

Private

Founded year

2016

Operating status

Acquired

Headcount range

1–10 employees

Short description

Proteologix was a preclinical-stage Redwood City biotech developing bispecific monoclonal antibodies (multi-specific molecules) for autoimmune/inflammatory diseases, oncology, atopic dermatitis, and asthma, acquired by Johnson & Johnson for $850 million in June 2024.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

akta.pro secondary industries

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Bispecific antibody therapeutics
• Autoimmune disease treatments
• Inflammatory disease therapies
• Oncology drug development
• Multi-specific molecule platform

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

Proteologix developed multi-specific (bispecific) monoclonal antibody therapeutics targeting autoimmune/inflammatory diseases and oncology indications, with a pipeline anchored by candidate PX119. The company was acquired by Johnson & Johnson in June 2024 for $850 million, with its assets (including formulations for atopic dermatitis and asthma) absorbed into J&J's dermatology portfolio.

Product overview

No product information available. Based on news sources, Proteologix was a biotechnology company focused on developing multi-specific molecules for autoimmune/inflammatory diseases and oncology indications, with a pipeline candidate called PX119. The company was acquired by Johnson & Johnson in June 2024. The current website is inactive and parked for sale.

Differentiator

Problem solved

Functional benefit

Products and services

• PX119 PX119 is a multi-specific (bispecific) monoclonal antibody candidate developed by Proteologix for the treatment of autoimmune/inflammatory diseases and oncology indications. It was positioned as a novel bispecific therapeutic designed to engage multiple disease targets simultaneously, addressing treatment gaps in conditions including atopic dermatitis and asthma. The candidate showed promise in preclinical studies and was a key asset driving Johnson & Johnson's $850 million acquisition of Proteologix in June 2024.
• Multi-Specific Molecule Platform Proteologix's proprietary multi-specific molecule platform is a technology for engineering bispecific monoclonal antibodies capable of simultaneously targeting multiple disease pathways. The platform underpins the company's pipeline in autoimmune/inflammatory diseases and oncology, and was the strategic technology asset that drove Johnson & Johnson's $850 million acquisition of Proteologix in June 2024 to bolster J&J's dermatitis and atopic dermatitis/asthma portfolio.

Quantifiable outcome

• PX119 shows promise in preclinical studies

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• MilliporeSigmacoreStrategic or Co-development Partner · 6 June 2023MilliporeSigma awarded Proteologix its 12th North American Advance Biotech Grant, providing in-kind products, services, and expert consultation to support drug development. Resources focus on multi-specific molecules for autoimmune/inflammatory diseases and oncology indications.

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• AnaptysBio: AnaptysBio develops antibody therapeutics for immunology and immuno-oncology indications. Comparable to Proteologix as a clinical-stage antibody developer with focus on inflammatory and immune-mediated diseases.
• Immunovant: Immunovant is a clinical-stage biotech developing FcRn-targeting biologics for autoimmune diseases. Comparable to Proteologix as a focused immunology biologics developer addressing similar autoimmune indications.
• Dermavant Sciences: Dermavant (a Roivant company) develops therapeutics for skin diseases including atopic dermatitis. Comparable to Proteologix given the shared focus on dermatitis therapies and immunology innovation.
• MacroGenics: MacroGenics develops bispecific antibodies (DART/TRIDENT platforms) with clinical-stage assets in oncology and autoimmune diseases. Directly comparable as a bispecific antibody developer with overlapping therapeutic focus.
• Zymeworks: Zymeworks developed the Azymetric bispecific antibody platform and has clinical-stage programs in autoimmune and oncology indications. Directly comparable to Proteologix's bispecific platform technology and therapeutic focus.
• Genmab: Genmab is a leading bispecific antibody platform company (DuoBody, HexaBody) developing therapeutics across oncology and autoimmune indications. Highly comparable to Proteologix as both build proprietary bispecific platforms for immunology and oncology.

Broad incumbents

• Sanofi (Dupixent franchise): Sanofi (with Regeneron) markets Dupixent, the leading atopic dermatitis biologic. Comparable as the dominant incumbent in the same atopic dermatitis market that Proteologix's pipeline is targeting.
• Eli Lilly (lebrikizumab/EBGLYSS): Eli Lilly markets EBGLYSS (lebrikizumab) for atopic dermatitis. Comparable as a major pharma with an approved IL-13 antibody competing in the same atopic dermatitis space targeted by Proteologix.
• AbbVie (Rinvoq/Skyrizi): AbbVie markets Rinvoq (atopic dermatitis) and Skyrizi in immunology. Comparable as a large immunology incumbent with competing atopic dermatitis therapies that Proteologix assets would need to differentiate against.

Emerging players

• AbCellera Biologics: AbCellera is an antibody discovery platform partnering with pharma to develop therapeutic antibodies. Comparable to Proteologix as an antibody engineering company, though AbCellera operates more as a discovery platform serving multiple partners.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proteologix